araag2/HINT huggingface dataset:
Clinical trial NCT02715115 (phase 2, status: completed)
Conditions: rett syndrome
ICD codes: F84.2
Drugs: nnz-2566, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of classic/typical Rett syndrome with a documented mutation of the MeCP2
             gene.

          -  Age 5 - 15 years.

          -  Weight at Screening and Baseline between 15.0 kg-100.0 kg (at least 15.0 kg and no
             greater than 100.0 kg).

          -  Each subject must be able to swallow the study medication provided as a liquid
             solution, or via gastrostomy tube.

        Exclusion Criteria:

          -  Actively undergoing neurological regression

          -  Abnormal QT interval, prolongation or significant cardiovascular history.

          -  Current treatment with insulin.

          -  Anti-convulsants with liver enzyme inducing effects.

          -  Unstable seizure profile.

          -  Excluded concomitant medications.

          -  Current clinically significant (as determined by the investigator). cardiovascular,
             renal, hepatic, or respiratory disease.

          -  Gastrointestinal disease which may interfere with the absorption, distribution,
             metabolism or excretion of the study medication.

          -  History of, or current cerebrovascular disease or brain trauma.

          -  History of, or current clinically significant endocrine disorder, e.g. hypo- or
             hyperthyroidism, or diabetes mellitus.

          -  History of, or current, malignancy.

          -  Significant hearing and/or visual impairments that may affect ability to complete the
             test procedures.

          -  Allergy to strawberry.
Clinical trial NCT02715960 (phase 2, status: unknown status)
Conditions: psoriasis vulgaris
ICD codes: L40.0
Drugs: acitretin capsules
SMILES: COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Diagnosed according to Classification criteria for Psoriasis vulgaris

          2. Patients aged 18 to 70 years (to the date of screening)

          3. PASI grade ≥7point

          4. Not treatment in the Topical corticosteroids, Immunosuppression, Biologicals agents or
             Tretinoin cream, Phototherapy nearly one months before enrolled.

          5. Total bilirubin < 1.5 x ULN, AST(SGOT)/ALT(SGPT) <2.5 x ULN if not liver metastases<5
             x ULN if known liver metastases, Creatinine clearance <1.5 x ULN

          6. Understanding the whole process of the study, voluntary participation and signed the
             informed consent

        Exclusion Criteria:

          1. Pregnant women, ready to pregnant or lactating women

          2. Have a serious heart, lung, kidney and other vital organs and endocrine system lesions
             and the history

          3. Patients is liver function abnormal persons (ALT above the center laboratory normal
             limit) or hepatitis b patient grain carriers

          4. Patients with chronic diarrhea, or peptic ulcer nearly 1 year

          5. Patients suffering from malignant tumor

          6. Patients suffering from acute and chronic infectious diseases

          7. Mental disorders, history of alcohol abuse, drug or other substance abuse

          8. Other cases which researchers believe that can not enroll
Clinical trial NCT02716311 (phase 2, status: active, not recruiting)
Conditions: non small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: afatinib, cetuximab
SMILES: CN(C)C\C=C\C(=O)NC1=C(O[C@H]2CCOC2)C=C2N=CN=C(NC3=CC(Cl)=C(F)C=C3)C2=C1, [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
Eligibility criteria:

        Principal Inclusion Criteria:

          -  Stage III or IV NSCLC, non irradiable non operable

          -  Non squamous NSCLC histologically or cytologically confirmed

          -  No previous treatment of NSCLC

          -  EGFR mutation (exon 19 deletion, L858R mutation, G719X , L861Q or S768I mutations or
             exon 19 insertion)

          -  Presence of at least one lesion that can be measured

          -  PS 0 or 1

        Principal Exclusion Criteria:

          -  Symptomatic brain metastasis or requiring immediate radiotherapy

          -  T790M mutation or exon 20 insertion

          -  Radiotherapy less than 2 weeks prior randomization including symptomatic radiotherapy

          -  Interstitial pneumopathy
Clinical trial NCT02716688 (phase 2, status: recruiting)
Conditions: esophageal cancer, s-1, radiotherapy
ICD codes: K22.2, K22.81, Q39.4, P78.83, I85.00, I85.01, I85.10
Drugs: s-1
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          1. Cytologically or histologically confirmed esophageal carcinoma;

          2. ECOG performance status: 0-1;

          3. No treatments prior to enrollment;

          4. At least one measurable lesion on CT, MRI or esophageal barium exam;

          5. Normal functions of heart, lung, liver, kidney and bone marrow;

          6. Blood exams qualified for chemotherapy, which included hemoglobulin ≥9 g/dl,
             neutrophil ≥1.5×109/L and platelet (PLT) ≥100×109/L, creatinine ≤1.5 UNL;

          7. Informed consent signed.

        Exclusion Criteria:

          1. Prior treatments of chemotherapy or irradiation;

          2. Poor bone marrow, liver and kidney functions, which would make chemotherapy
             intolerable;

          3. Contraindication for irradiation: complete obstruction of esophagus, deep esophageal
             ulcer, fistula to mediastinum, or haematemesis;

          4. Participating in other clinical trials;

          5. Clinically significant and uncontrolled major medical conditions including but not
             limited to: active uncontrolled infection, symptomatic congestive heart failure,
             Unstable angina pectoris or cardiac arrhythmia, psychiatric illness/ social situation
             that would limit compliance with study requirements; any medical condition, which in
             the opinion of the study investigator places the subject at an unacceptably high risk
             for toxicities;

          6. The subject has had another active malignancy within the past five years except for
             cervical cancer in site, in situ carcinoma of the bladder or non-melanoma carcinoma of
             the skin.
Clinical trial NCT02716766 (phase 2, status: completed)
Conditions: carcinoma, hepatocellular, secondary
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: sorafenib, capecitabine, oxaliplatin
SMILES: CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Advanced or metastatic hepatocellular carcinoma (HCC) not suitable for surgery or
             various loco-regional therapies.

          -  Diagnosis of HCC confirmed either by cyto-histological confirmation or by non-invasive
             criteria according to the European Association for Study of Liver disease (EASL)
             criteria.

          -  Child-Pugh A or B7 cirrhosis.

          -  Eastern Co-Operative Group (ECOG) performance status ≤ 2.

          -  Life expectancy of ≥ 12 weeks.

          -  Adequate organ function (blood transfusion or use of biologic response modifiers is
             not permitted).

          -  Measurable disease with at least one lesion, which is at least 1 cm in one dimension
             on computed tomography (CT) or magnetic resonance imaging (MRI).

          -  Able and willing to meet all protocol-required treatments, investigations and visits.

          -  Signed written informed consent form.

        Exclusion Criteria:

          -  Prior systemic therapy for advanced HCC.

          -  Central nervous system (CNS) metastasis.

          -  History of liver transplantation.

          -  Peripheral sensory neuropathy with functional impairment before the first cycle of
             treatment.

          -  History of cardiac disease.

          -  Uncontrolled hypertension.

          -  Women who are pregnant or breast-feeding, or women of child-bearing potential who are
             unable or unwilling to practice a highly effective means of contraception.

          -  Substance abuse, medical, psychological or social conditions that may interfere with
             the patient's participation in the study or evaluation of study results.
Clinical trial NCT02719158 (phase 2, status: completed)
Conditions: acute otitis media, aomt
ICD codes: H65.03, H65.00, H65.01, H65.02, H65.06, H65.193, H65.04
Drugs: 6 mg ciprofloxacin, 12 mg ciprofloxacin
SMILES: OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O, OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O
Eligibility criteria:

        Inclusion Criteria includes, but is not limited to:

          -  Subject is a male or female aged 6 months to 17 years, inclusive

          -  Subject has a clinical diagnosis of acute otitis media with tympanostomy tubes (AOMT)

          -  Subject's caregiver is willing to comply with the protocol an attend all study visits

        Exclusion Criteria includes, but is not limited to:

          -  Subject has a history of sensorineural hearing loss

          -  Subject has tympanic membrane perforation other than the surgical tympanostomy tube
             perforation

          -  Subject has a history of known immunodeficiency disease
Clinical trial NCT02720523 (phase 2/phase 3, status: active, not recruiting)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: placebo, upadacitinib
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of rheumatoid arthritis (RA) for >= 3 months who also fulfill the 2010
             American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR)
             classification criteria for RA.

          -  Subjects have been receiving conventional synthetic disease-modifying anti-rheumatic
             drug (csDMARD) therapy >= 3 months and on a stable dose for >= 4 weeks prior to the
             first dose of study drug.

          -  Subject has >= 6 swollen joints (based on 66 joint counts) and >= 6 tender joints
             (based on 68 joint counts) at Screening and Baseline Visits.

          -  Subjects with prior exposure to at most one biological disease-modifying
             anti-rheumatic drug (bDMARD) may be enrolled (up to 20% of total number of subjects)
             after the required washout period. Specifically, prior to enrollment:

               1. Subjects with limited exposure to bDMARD (< 3 months) OR

               2. Subjects who are responding to bDMARD therapy but had to discontinue due to
                  intolerability (regardless of treatment duration).

        Exclusion Criteria:

          -  Prior exposure to any Janus kinase (JAK) inhibitor

          -  Subjects who are considered inadequate responders (lack of efficacy) to bDMARD
             therapy, after minimum 3 months treatment, as determined by the Investigator.

          -  History of any arthritis with onset prior to age 17 years or current diagnosis of
             inflammatory joint disease other than RA (including but not limited to gout, systemic
             lupus erythematosus, psoriatic arthritis, axial spondyloarthritis [SpA] including
             ankylosing spondylitis and non-radiographic axial SpA, reactive arthritis, overlap
             connective tissue diseases, scleroderma, polymyositis, dermatomyositis, fibromyalgia
             [currently with active symptoms]). Current diagnosis of secondary Sjogren's Syndrome
             is permitted.
Clinical trial NCT02722967 (phase 2, status: completed)
Conditions: schizophrenia, major depressive disorder, bipolar i disorder
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9, F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40, F31.70, F31.71, F31.72, F31.73, F31.74, F31.75, F31.76
Drugs: aripiprazole + iem (ingestible event marker)
SMILES: ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Primary diagnosis of Schizophrenia (SCH), Major Depressive Disorder (MDD), or Bipolar
             1 Disorder (BP1), per the Diagnostic and Statistical Manual of Mental Disorders, Fifth
             Edition (DSM-5)

          -  Must be able to swallow tablets

          -  Currently taking a stable daily dose of oral aripiprazole

          -  Must have capacity to utilize the technology

          -  Skin in area of patch application must be free of any skin disorders or dermatological
             problems

        Exclusion Criteria:

          -  Subjects using long acting injectable antipsychotic medications

          -  Subjects likely to be incapable of using the Digital Medicine System even with
             assistance

          -  Subjects who present serious risk of suicide

          -  History of epilepsy or seizures

          -  History of hypersensitivity to antipsychotic agents, adhesive tape or any component of
             the sensor skin patch or ingestible event marker

          -  Current history of substance use disorder meeting DSM-5 criteria

          -  Subject with unstable mood, acute psychosis or exhibiting symptoms requiring
             hospitalization
Clinical trial NCT02724527 (phase 2, status: unknown status)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: cavosonstat, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed diagnosis of CF, heterozygous for F508del-CFTR and a gating mutation that is
             approved for treatment with ivacaftor (G551D, G1244E, G1349D, G178R, G551S, S1251N,
             S1255P, S549N, or S549R)

          -  Have been treated with chronic ivacaftor twice daily for at least 6 months prior to
             Screening (date of consent) and are currently being treated with commercially
             available Ivacaftor

          -  Negative serum pregnancy test

          -  Weight ≥ 40 kg at screening

          -  Oxygen saturation by pulse oximetry ≥ 90% breathing ambient air, at screening

        Exclusion Criteria:

          -  Any acute infection, including acute upper or lower respiratory infections and
             pulmonary exacerbations that require treatment that has completed within 2 weeks of
             Study Day 1 or hospitalization discharge within 2 weeks of Study Day 1

          -  Recent infection (per investigator discretion) with organisms associated with more
             rapid decline in pulmonary status, for example: Burkholderia cenocepacia, Burkholderia
             dolosa, and Mycobacterium abscessus

          -  Any change in the regimen for chronic therapies for CF lung disease (e.g., Pulmozyme®,
             hypertonic saline, Azithromycin, TOBI®, Cayston®) within 4 weeks of Study Day 1

          -  Blood hemoglobin < 10 g/dL at screening

          -  Serum albumin < 2.5 g/dL at screening

          -  Abnormal liver or renal function

          -  History of ventricular tachycardia or other clinically significant ventricular
             arrhythmias

          -  History, including the screening assessment, of prolonged QT and/or QTcF (Fridericia's
             correction) interval (> 450 msec for men; > 470 msec for women)

          -  History of solid organ or hematological transplantation

          -  History of alcohol abuse or drug abuse (including cannabis, cocaine, and opioids) in
             the year prior to screening

          -  Use of continuous (24 hr/day) or nocturnal supplemental oxygen
Clinical trial NCT02727907 (phase 2/phase 3, status: unknown status)
Conditions: multiple sclerosis
ICD codes: G35, C81.18
Drugs: bcd-033 (interferon beta 1a), rebif (interferon beta 1a), placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Age 18-55

          2. Patients of both genders with Multiple Sclerosis (McDonald criteria 2010)

          3. No relapses 28 days before randomisation

          4. Expanded Disability Status Scale score 0-5,5

        Exclusion Criteria

          1. Primary or secondary progression of Multiple Sclerosis

          2. Expanded Disability Status Scale score more then 5,5

          3. Severe depression, suicide ideas and/or attempts

          4. Systemic corticosteroid application in 30 days before randomisation
Clinical trial NCT02728206 (phase 2, status: completed)
Conditions: hepatitis c virus infection
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: sof/vel
SMILES: [H][C@](N=C(O)OC)(C(C)C)C(=O)N1[C@@]([H])(C)CC[C@@]1([H])C1=NC2=C(N1)C1=CC3=C(C=C1C=C2)C1=C(CO3)C=C(C=C1)C1=CN=C(N1)[C@]1([H])C[C@]([H])(COC)CN1C(=O)[C@]([H])(N=C(O)OC)C1=CC=CC=C1
Eligibility criteria:

        Key Inclusion Criteria:

          -  HCV-infected, male and non-pregnant/non-lactating females, who are undergoing liver
             transplantation

        Key Exclusion Criteria:

          -  Receiving an HCV-infected liver

          -  HIV or hepatitis B virus (HBV) co-infected

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Clinical trial NCT02730208 (phase 2, status: completed)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: tezacaftor/ivacaftor, ivacaftor, placebo, placebo
SMILES: CC(C)(CO)C1=CC2=CC(NC(=O)C3(CC3)C3=CC=C4OC(F)(F)OC4=C3)=C(F)C=C2N1C[C@@H](O)CO, CC(C)(C)C1=CC(=C(O)C=C1NC(=O)C1=CNC2=CC=CC=C2C1=O)C(C)(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Homozygous for the F508del CFTR mutation

          -  Confirmed diagnosis of CF

          -  Percent predicted forced expiratory volume (ppFEV1) ≥70% of predicted normal for age,
             sex, and height during screening.

          -  Stable CF disease as judged by the investigator

        Exclusion Criteria:

          -  History of any comorbidity that, in the opinion of the investigator, might confound
             the results of the study or pose an additional risk in administering study drug to the
             subject.

          -  An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in
             therapy (including antibiotics) for pulmonary disease within 28 days before Day 1
             (first dose of study drug)

          -  Pregnant or nursing females.

          -  Sexually active subjects of reproductive potential who are not willing to follow the
             contraception requirements.

          -  Any contraindication to undergoing chest imaging, as per the site's institutional
             guidelines
Clinical trial NCT02730455 (phase 2, status: completed)
Conditions: acute ischemic stroke
ICD codes: I25.5, H47.013, H93.013, G45.9, H47.011, H47.012, H47.019
Drugs: natalizumab, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Clinical diagnosis of supratentorial acute ischemic stroke defined by LKN ≤24 hours
             prior to study treatment initiation.

          -  Score of 5 to 23 points, inclusive, on the NIHSS at Screening for subjects initiating
             treatment ≤9 hours from LKN. Note: NIHSS eligibility must be confirmed within 60
             minutes prior to randomization.

          -  Score of 5 to 15 points, inclusive, on the NIHSS at Screening for subjects initiating
             treatment >9 to ≤24 hours from LKN. Note: NIHSS eligibility must be confirmed within
             60 minutes prior to randomization.

          -  Prior to index stroke, patient was able to perform basic activities of daily living
             without assistance: dressing, eating, walking, bathing, and using the toilet.

          -  For those subjects who underwent a cranial MRI, there is at least 1 acute infarct with
             a diameter of ≥2 cm on baseline brain diffusion-weighted imaging.

        Key Exclusion Criteria:

          -  Lacunar or isolated brainstem or cerebellar stroke based on clinical assessment and
             available acute imaging studies performed under the standard of care.

          -  Presence of acute intracranial hemorrhage on acute brain CT or MRI. However, petechial
             hemorrhages of ≤1 cm are not exclusionary.

          -  Severe stroke defined by imaging criteria based on either one of the following:

          -  Alberta Stroke Program Early CT (ASPECT) score of 0 to 4 based on head CT or

          -  Acute infarct volume on MRI diffusion weighed imaging greater than or equal to 70 mL

          -  Seizure at the onset of stroke.

          -  Known history of prior treatment with natalizumab.

          -  Known history of active viral hepatitis B or C.

          -  Signs and symptoms of active or acute infection.

        NOTE: Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT02735317 (phase 2, status: unknown status)
Conditions: nasopharyngeal neoplasms, stomatitis
ICD codes: A36.1, B87.3, B08.61, B37.0, A69.0, K12.1, B08.4
Drugs: oral ulcer gargle (forrad®), quadruple mixture, composed of dexamethasone, gentamicin, vitamin b12, and procaine
SMILES: CCN(CC)CCOC(=O)C1=CC=C(N)C=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Pathologically confirmed and previously untreated nasopharyngeal carcinoma.

          2. Age ≥ 18 years and ≤ 65 years.

          3. Karnofsky performance status (KPS) score ≥ 70.

          4. Planned to receive radiotherapy alone or concurrent chemoradiotherapy, with
             intensity-modulated radiation therapy (IMRT).

          5. Adequate bone marrow function: while blood cell >= 3,000/μL, absolute neutrophil count
             >= 1,500/μL, hemoglobin >= 100g/L, platelet >= 75,000/μL.

          6. Life expectancy of >= 3 months.

        Exclusion Criteria:

          1. Known allergic reaction to any component of Oral Ulcer Gargle (FORRAD®) or quadruple
             mixture, which is composed of dexamethasone, gentamicin, vitamin B12, and procaine, or
             severe allergic constitution.

          2. Other conditions that the investigators consider as inappropriate for enrolling into
             this study.
Clinical trial NCT02735863 (phase 2, status: completed)
Conditions: hiv infection
ICD codes: Z21
Drugs: abx464, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients infected with HIV;

          -  Patients with HIV plasma viral load ≤ 50 copies mL-1 during the 6 months prior to
             screening with a maximum of 2 blips during this period;

          -  Patients treated by DRV/RTV or DRV/COBI as a monotherapy for at least 8 weeks prior to
             baseline;

          -  Patients' HIV plasma viral load ≤100,000 copies mL-1 at any time (apart from primary
             infection if recorded);

          -  Patients' CD4+ T cells count ≥ 250 cells per mm3 at any time since diagnosis;

          -  Patients with CD4+ T cells count ≥ 600 cells per mm3 at screening;

          -  Man or woman aged 18-65 years;

        Exclusion Criteria:

          -  Patient displaying any HIV protease inhibitor resistance mutation as listed in the
             current version of the HIV drug resistance database (Stanford University);

          -  Patient having had previously a viral load ≥ 500 copies mL-1 confirmed by a second
             measure since the initiation of the current ART;

          -  History of an AIDS-defining clinical illness;

          -  Concomitant AIDS-related opportunistic infection;